Mediator complex subunit 1 architects a tumorigenic Treg cell program independent of inflammation.
Ontology highlight
ABSTRACT: While immunotherapy has revolutionized cancer treatment, its safety has been hampered by immunotherapy-related adverse events. Unexpectedly, we show that Mediator complex subunit 1 (MED1) is required for T regulatory (Treg) cell function specifically in the tumor microenvironment. Treg cell-specific MED1 deletion does not predispose mice to autoimmunity or excessive inflammation. In contrast, MED1 is required for Treg cell promotion of tumor growth because MED1 is required for the terminal differentiation of effector Treg cells in the tumor. Suppression of these terminally differentiated Treg cells is sufficient for eliciting antitumor immunity. Both human and murine Treg cells experience divergent paths of differentiation i
SUBMITTER: Chaudhuri SM
PROVIDER: S-EPMC10983042 | biostudies-literature | 2024 Mar
REPOSITORIES: biostudies-literature
ACCESS DATA